1. Scrip
  2. >>R&D
  3. >>Clinical Trials

ASH In Review: Roche Refreshes Hematology Portfolio With Robust New Drugs

 
• By Emily Hayes

Phase II data for antibody-drug conjugate polatuzumab vedotin in diffuse large B cell lymphoma suggest potential for a cure if the drug were given up front, Roche says on investor call after American Society of Hematology meeting.

RedBloodCellsOnWhite_1200x675

Data presented at the American Society of Hematology meeting fleshed out the profile of Roche's newly approved hemophilia drug Hemlibra for physicians, promised to catapult chronic lymphocytic leukemia drug Venclexta from a low sales base and introduced polatuzumab vedotin as a robust therapy for diffuse large B cell lymphoma.

This year's American Society of Hematology (ASH) meeting from Dec. 9-12 in Atlanta capped a year of portfolio renewal at Roche following US FDA approval in November for Hemlibra (emicizumab) as a weekly injection to treat hemophilia A in patients with inhibitors as well as the release of positive results for the PD-L1 inhibitor Tecentriq (atezolizumab), execs said during a Dec. 13 investor call. (Also see "Roche's Tecentriq-Avastin Combo Improves PFS In Kidney Cancer Too" - Scrip, 11 December, 2017.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.